CTC
TGTX icon

Central Trust Company’s TG Therapeutics TGTX Stock Holding History

Central Trust Company’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-16
Closed – – 1455
2022
Q1 		$0 Sell
16
-384
-96% -$4.44K ﹤0.01% 1482
2021
Q4 		$8K Hold
400
– – ﹤0.01% 1093
2021
Q3 		$13K Hold
400
– – ﹤0.01% 998
2021
Q2 		$16K Buy
+400
New +$15.7K ﹤0.01% 931

Other funds holding TGTX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Central Trust Company's TGTX Position: Q2 2022 in Review

Central Trust Company sold out of TG Therapeutics (TGTX) in Q2 2022, closing a stake of 16 shares.

Central Trust Company first reported a position in TGTX in Q2 2021 and held it in 4 quarters. The position peaked at $16K in Q2 2021. 174 funds tracked by Wall St. Rank hold TGTX as of Q2 2022.

  • Central Trust Company reported no remaining TG Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Central Trust Company sold 16 TG Therapeutics shares in Q2 2022.
  • Central Trust Company first reported a position in TG Therapeutics in Q2 2021 and held it in 4 quarters.
  • Central Trust Company's TG Therapeutics position peaked at $16K in Q2 2021.
  • 174 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2022.

Based on Central Trust Company's 13F filing for Q2 2022, filed 9 Aug 2022.